Open AccessBortezomib-Induced Blepharitis: a Case Report
Publication year - 2020
Publication title -
international journal of cancer research and therapy
Language(s) - English
Resource type - Journals
ISSN - 2476-2377
DOI - 10.33140/ijcrt.05.01.02
Subject(s) - bortezomib , blepharitis , eyelid , medicine , multiple myeloma , proteasome inhibitor , dermatology , ophthalmology
Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma, and has knownmanageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causingvisual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature.Case: we present a case of 76 year old lady with multiple myeloma who developed bortezomib-induced blepharitis andchalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib.